StockNews.AI
VALN
StockNews.AI
21 days

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm

1. Bragar Eagel & Squire investigates Valneva for potential securities violations. 2. CDC noted hospitalizations after Valneva's chikungunya vaccine, impacting stock price. 3. FDA suspended IXCHIQ marketing due to safety concerns, causing further stock decline. 4. Investors encouraged to discuss legal rights following significant stock losses. 5. Investigation may highlight unlawful business practices affecting investor confidence.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Recent safety concerns and regulatory actions have led to significant stock price declines.

How important is it?

The article addresses legal risks and losing investor confidence, directly affecting VALN's price.

Why Short Term?

Immediate legal investigations and market reactions suggest topical but transient impacts.

Related Companies

PFEJNJMRNA
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Valneva and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Valneva SE (“Valneva” or the “Company”) (NASDAQ:VALN) on behalf of Valneva stockholders. Our investigation concerns whether Valneva has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 25, 2025, the U.S. Centers for Disease Control and Prevention ("CDC") posted a notice on its website announcing that "CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva's chikungunya virus vaccine] among people 65 years of age and older." Following the CDC's announcement and subsequent reporting by media outlets, Valneva's American Depositary Receipt ("ADR") price fell $1.06 per ADR, or 13.57%, over the following four trading sessions, to close at $6.75 per ADR on February 28, 2025. Then, on August 22, 2025, the U.S. Food and Drug Administration announced that it had suspended the marketing application for IXCHIQ due to safety concerns. On this news, Valneva's ADR price fell $2.21 per ADR, or 18.99%, to close at $9.43 per ADR on August 25, 2025. If you purchased or otherwise acquired Valneva shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News